24563-96-0

Basic information

• Product Name: 1-hydroxymethyl-abietane p-methylbenzenesulfonate
• Synonyms: 1-hydroxymethyl-abietane p-methylbenzenesulfonate
• CAS NO: 24563-96-0
• Molecular Weight: 442.663
• Mol File: 24563-96-0.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 1-hydroxymethyl-abietane p-methylbenzenesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: 1-hydroxymethyl-abietane p-methylbenzenesulfonate(24563-96-0)
• EPA Substance Registry System: 1-hydroxymethyl-abietane p-methylbenzenesulfonate(24563-96-0)

Safety Data

• Hazardous Substances Data: 24563-96-0(Hazardous Substances Data)

Upstream product

• 514-10-3 abietic acid 
• 631-71-0 ethyl abietate 
• 666-84-2 abietinol 
• 98-59-9 p-toluenesulfonyl chloride 
• 127-25-3 methyl abietate 

Downstream Products

• 666-84-2 abietinol 
• 3772-55-2 dehydroabietinol 

Relevant articles and documents

Design and synthesis of tricyclic terpenoid derivatives as novel PTP1B inhibitors with improved pharmacological property and in vivo antihyperglycaemic efficacy

Overexpression of protein tyrosine phosphatase 1B (PTP1B) induces insulin resistance in various basic and clinical research. In our previous work, a synthetic oleanolic acid (OA) derivative C10a with PTP1B inhibitory activity has been reported. However, C10a has some pharmacological defects and cytotoxicity. Herein, a structure-based drug design approach was used based on the structure of C10a to elaborate the smaller tricyclic core. A series of tricyclic derivatives were synthesised and the compounds 15, 28 and 34 exhibited the most PTP1B enzymatic inhibitory potency. In the insulin-resistant human hepatoma HepG2 cells, compound 25 with the moderate PTP1B inhibition and preferable pharmaceutical properties can significantly increase insulin-stimulated glucose uptake and showed the insulin resistance ameliorating effect. Moreover, 25 showed the improved in vivo antihyperglycaemic potential in the nicotinamide–streptozotocin-induced T2D. Our study demonstrated that these tricyclic derivatives with improved molecular architectures and antihyperglycaemic activity could be developed in the treatment of T2D.

Preparation method of 15-hydroxyl dehydrogenated abietane and intermediate of 15-hydroxyl dehydrogenated abietane

The invention discloses a preparation method of 15-hydroxyl dehydrogenated abietane and an intermediate of 15-hydroxyl dehydrogenated abietane. The preparation method comprises the following steps: converting a compound 1 into a compound 5, and converting the compound 5 into a compound 8. According to the method for preparing the compound 8, the problem that a product cannot be separated out of a glacial acetic acid solution because reaction impurities are remarkably increased when the feeding quantity is increased at the hydrogen bromide addition step in the existing synthesis route is solved through continuous screening of a process route. Furthermore, the method provided by the invention is high in yield at each step, easy to amplify and suitable for industrialized large-scale production. (The formula is as shown in the description.).

Synthesis of (+)-amberketal and its analog from l-abietic acid

(+)-Amberketal (1) and its analog (2) have been synthesized from commercially available l-abietic acid (3) by a selective reduction of an unsaturated aldehyde in the presence of a ketone and simultaneous reduction of an iodide using an aqueous suspension of Raney Ni as the key step.